CVS Stock Price Today (September 2026) — CVS Health Corporation Analysis & Key Metrics 2026-09-03
CVS Health Corporation (CVS) is trading at $97.20, down 0.03% today (as of September 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $116.08 (19.4% upside).
- Volatility remains elevated (22.28% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.10% YoY) alongside significant competitive pressures.
CVS Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
CVS Health Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $181.57B
P/E Ratio
Forward P/E: 11.04
Revenue Growth
Year over Year
Analyst Target
+19.4% upside potential
Key Investor Questions About CVS
What investors need to know before buying
Based on current market data, CVS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 55.55)
- Fundamentals say: Caution warranted (high leverage concerns)
CVS's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CVS investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $76.31B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CVS stock traded between $69.51 and $110.68—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 22.28% annualized volatility and β=0.25, the stock exhibits low sensitivity to market moves—making CVS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
UnitedHealth Stock Recovered Before Its Margins Did
UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.
CVS Stock Has Left Its Peers Behind. Or Has It?
The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.
Small business guide: How to survive year one
The founders of Kemo Sabe, Slick Chicks, Sunhome Saunas and more share important lessons on surviving year one in small business. Plus, everything you need to know before the business tax filing extension deadline hits this year.
Here's How CVS' Improving Balance Sheet Supports Deleveraging
CVS Health's strong cash generation, higher operating cash flow outlook and disciplined capital deployment support continued deleveraging in 2026.
CVS Health (CVS) Climbed Today, But What Is Catching The Market's Attention?
CVS Health (CVS) recently raised its 2026 adjusted earnings per share guidance to a range of US$7.90 to US$8.10 and outlined plans to invest US$20 billion in healthcare technology and data infrastructure. Those guidance comments and investment plans have landed in a stock that has already seen momentum pick up. CVS Health’s 1 day share price return of 3.93% and 7 day return of 5.06% come after a 30 day decline of 6.54%, while the year to date share price return of 21.80% and 1 year total...
Why CVS Stock Rallied Tuesday Morning
Wall Street is warming to the prospects of the healthcare giant.
Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest
Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.
UNH Stock Gets Cheaper Only If The Margins Come Back
Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.
Elizabeth Warren Says ‘A Handful of CEOs’ Dictate Americans’ Choices: ‘We Need to Block Mega-Mergers’
Sen. Elizabeth Warren (D-Mass.) warned that growing corporate consolidation is giving a small group of powerful companies and CEOs outsized influence over Americans’ everyday choices, urging regulators to block mega-mergers. Warren Targets Corporate Consolidation On Saturday, in a post on...
200,000 Medicare users sprint to CVS and Walgreens to snatch up $50 obesity drugs — millions more are still missing out
Weight loss drug consumers get a Medicare cost break, but it has a deadline.
Explore More Analysis for CVS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about CVS Health Corporation
CVS Health Corporation (CVS) is currently trading at $97.20. The RSI (14-day) is at 55.6, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $116.08 implies 19.4% upside from current levels. Volatility is moderate at 22.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CVS Health Corporation (CVS): The trailing P/E ratio is 25.65, which is in line with broader market averages. The forward P/E is 11.04, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.25, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.56. Price-to-Sales is 0.30. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering CVS, the consensus price target is $116.08. This represents a 19.4% upside from the current price of $97.20. The range spans from a low target of $103.00 to a high target of $148.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, CVS Health Corporation (CVS) pays a dividend with a current yield of approximately 2.74%. The annualized dividend rate is $2.66 per share. The payout ratio is 70.2%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-07-23T00:00:00.000Z.
Key risks for CVS Health Corporation (CVS) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CVS Health Corporation's (CVS) current debt and financial health profile: Total debt stands at $76.31B. The debt-to-equity ratio is 95.50, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.62. The company holds $13.96B in cash and equivalents. Free cash flow is positive at $8.08B, providing a cushion for debt servicing and shareholder returns.